Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study

Authors

Chunqiao Tian, Precision Therapeutics, Inc.
Daniel J. Sargent, Mayo Clinic
Thomas C. Krivak, Western Pennsylvania Hospital
Matthew A. Powell, Washington University School of Medicine in St. Louis
Michael J. Gabrin, Precision Therapeutics, Inc.
Stacey L. Brower, Precision Therapeutics, Inc.
Robert L. Coleman, University of Texas M.D. Anderson Cancer Center

Journal

British Journal of Cancer

Publication Date

2014

Volume

111

Issue

5

Inclusive Pages

843-850

Document Type

Open Access Publication

DOI

10.1038/bjc.2014.375

Rights and Permissions

C Tian, et al. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study. British Journal of Cancer (2014) 111, 843–850. doi:10.1038/bjc.2014.375 www.bjcancer.com Copyright 2014 Cancer Research UK This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

Recommended Citation

Tian, Chunqiao; Sargent, Daniel J.; Krivak, Thomas C.; Powell, Matthew A.; Gabrin, Michael J.; Brower, Stacey L.; and Coleman, Robert L., "Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study." British Journal of Cancer. 111, 5. 843-850. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/4035